

*Sub I* 7. (Reiterated) The method of claim 6, wherein the method does not comprise selecting an agent based on its ability to inhibit FKBP-12 rotamase activity.

*Please cancel claims 9 and 10, without prejudice to renewal.*

*G2 Sub H1* 11. (Twice Amended) The method of claim 6, further comprising selecting a FK506 analog that does not inhibit rotamase activity.

*G3* 15. (Twice Amended) The method of claim 6, wherein the assay for activity in promoting nerve cell growth comprises exposing a cell to the selected FK506 analog and determining if neurite outgrowth is promoted.

*Please cancel claims 16-17, without prejudice to renewal.*

20. (Twice Amended) A method of identifying a FK506 analog that stimulates nerve cell growth, the method comprising:

*G4* screening a plurality of FK506 analogs for binding to FKBP-12;

selecting one or more FK506 analogs of interest that has a  $K_d$  for FKBP-12 of at least 100  $\mu$ M; and

assaying of one or more of the analogs of interest for activity in promoting nerve cell growth.

*Please cancel claim 21, without prejudice to renewal.*

#### REMARKS

Claims 9-10, 16-17 and 21 are canceled herein without prejudice to renewal. Claims 6, 11 and 20 are amended herein. Support for the amending language of claims 6 and 20 can be found